Relay Therapeutics Correlations
RLAY Stock | USD 3.36 0.16 4.55% |
The current 90-days correlation between Relay Therapeutics and Sana Biotechnology is 0.37 (i.e., Weak diversification). The correlation of Relay Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak. If the correlation is 0, the equities are not correlated; they are entirely random.
Relay Therapeutics Correlation With Market
Very weak diversification
The correlation between Relay Therapeutics and DJI is 0.41 (i.e., Very weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Relay Therapeutics and DJI in the same portfolio, assuming nothing else is changed.
Moving together with Relay Stock
0.65 | A | Agilent Technologies Earnings Call This Week | PairCorr |
0.75 | JNJ | Johnson Johnson | PairCorr |
0.8 | MRK | Merck Company | PairCorr |
0.85 | PFE | Pfizer Inc Earnings Call This Week | PairCorr |
0.72 | GILD | Gilead Sciences Earnings Call This Week | PairCorr |
0.63 | ABBV | AbbVie Inc | PairCorr |
0.86 | AMGN | Amgen Inc Earnings Call This Week | PairCorr |
0.86 | BNTX | BioNTech SE Earnings Call This Week | PairCorr |
0.66 | MGRM | Monogram Orthopaedics | PairCorr |
0.68 | PTHL | Pheton Holdings | PairCorr |
0.82 | METROPOLIS | Metropolis Healthcare Earnings Call This Week | PairCorr |
0.74 | BTC | BTC Health | PairCorr |
0.71 | ZOTA | Zota Health Care | PairCorr |
0.67 | CICHF | China Construction Bank | PairCorr |
0.72 | MHO | MI Homes | PairCorr |
0.64 | UNCFF | UniCredit SpA | PairCorr |
0.81 | B | Barrick Mining Symbol Change | PairCorr |
Moving against Relay Stock
0.86 | ERNA | Eterna Therapeutics | PairCorr |
0.59 | TELO | Telomir Pharmaceuticals, | PairCorr |
0.54 | CLOV | Clover Health Investments Earnings Call This Week | PairCorr |
0.44 | MOLN | Molecular Partners | PairCorr |
0.39 | LPCN | Lipocine | PairCorr |
Related Correlations Analysis
Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Relay Stock performing well and Relay Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Relay Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
---|---|---|---|---|---|---|---|---|---|---|
RVMD | 1.83 | (0.26) | 0.00 | (0.15) | 0.00 | 3.60 | 18.30 | |||
BPMC | 1.86 | 0.62 | 0.47 | 0.70 | 0.61 | 5.43 | 26.28 | |||
SANA | 4.97 | 1.25 | 0.31 | 0.86 | 3.65 | 12.50 | 34.30 | |||
KYMR | 2.81 | 0.36 | 0.12 | 0.37 | 3.09 | 5.70 | 48.99 | |||
GLUE | 3.21 | (0.22) | (0.01) | 0.03 | 4.30 | 7.27 | 18.03 | |||
NRIX | 2.77 | (0.23) | (0.03) | 0.02 | 3.32 | 6.62 | 21.48 | |||
PCVX | 2.73 | (0.15) | 0.00 | 0.06 | 3.50 | 6.93 | 21.28 | |||
ITOS | 2.08 | 0.57 | 0.22 | 2.93 | 1.67 | 5.84 | 19.21 |
Relay Therapeutics Corporate Management
Deborah Palestrant | Vice Strategy | Profile | |
MA MBA | Pres CEO | Profile | |
Thomas Catinazzo | Chief Officer | Profile | |
Andy Porter | Chief Officer | Profile | |
Jim Watters | Chief Research | Profile |